Dyne Therapeutics Reports $193.6 Million Q3 Net Loss
Dyne reported a Q3 2026 net loss of $193.6 million, or $1.06 per share, versus a $108.0 million loss, or $0.76 per share, in Q3 2025. Cash and marketable securities totaled $1.134 billion at September 30, 2026, and are expected to fund operations into Q2 2028.
Story updates
12:45:22 PM UTC
SquawkNews
Dyne Therapeutics reported a third-quarter 2026 net loss of $193.6 million, compared with $108.0 million a year earlier. Research and development expenses rose to $161.7 million, while cash, cash equivalents and marketable securities totaled $1.134 billion at quarter-end. The company also outlined…
Dyne reported a Q3 2026 net loss of $193.6M, or $1.06 per share, versus $108.0M, or $0.76 per share, in Q3 2025. Cash and marketable securities were $1.134B at September 30, 2026, expected to fund operations into Q2 2028.Material DetailsContext by AI AnalystThis is a clinical-stage biotech advancin…